Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Edwards Lifesciences Corp ONE EDWARDS WAY IRVINE CA 92614 USA

www.edwards.com Employees: 19,800 P: 949-250-2500 F: 949-250-2525

Description:

Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.

Key Statistics

Overview:

Market Capitalization, $K 44,122,936
Enterprise Value, $K 43,575,936
Shares Outstanding, K 589,800
Annual Sales, $ 6,005 M
Annual Net Income, $ 1,402 M
Last Quarter Sales, $ 1,354 M
Last Quarter Net Income, $ 3,071 M
EBIT, $ 1,507 M
EBITDA, $ 1,652 M
60-Month Beta 1.12
% of Insider Shareholders 1.27%
% of Institutional Shareholders 79.46%
Float, K 582,310
% Float 98.73%
Short Volume Ratio 0.41

Growth:

1-Year Return -2.12%
3-Year Return -41.81%
5-Year Return -4.34%
5-Year Revenue Growth 61.30%
5-Year Earnings Growth 59.87%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.67 on 10/24/24
Next Earnings Date 02/04/25
Earnings Per Share ttm 2.67
EPS Growth vs. Prev Qtr -4.29%
EPS Growth vs. Prev Year 13.56%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 3-1 on 06/01/20

EW Ratios

Ratio
Price/Earnings ttm 28.02
Price/Earnings forward 29.26
Price/Earnings to Growth 3.68
Return-on-Equity % 20.76%
Return-on-Assets % 15.27%
Profit Margin % 23.35%
Debt/Equity 0.06
Price/Sales 7.35
Price/Cash Flow 27.08
Price/Book 4.69
Book Value/Share 15.96
Interest Coverage 91.80
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar